Cancer September 2004 PMID 15368335

Patterns of high-dose morphine use in a home-care hospice service: should we be afraid of it?

Michaela Bercovitch, Abraham Adunsky

Download social card

Mentions

Peak: 2 in Jun 2023

across 2 sources since Jun 2023

Extended reach

171,379

potential audience

Total likes

3,063

Video views

170,820

Mentions per month

Jun 2023 – Nov 2024

Where it's discussed

YouTube5 videos
X / Twitter1 posts

AI synopsis

What people are saying

The overall discussion shows limited depth, exemplified by the brief disagreement 'You're wrong,' which indicates skepticism but no further elaboration or exploration of the article's findings. The tone hints at disagreement rather than constructive analysis or interest, leading to a neutral overall impact.

AgreementLow agreement

The discussion suggests some disagreement with the publication, as seen in the brief dismissive comment, 'You're wrong,' indicating skepticism or rejection.

InterestNeutral interest

The interest level appears neutral since there is little elaboration or curiosity shown beyond the disagreement, reflecting neither high nor low engagement.

EngagementLow engagement

The engagement is minimal, with a quick dismissive response that doesn't delve into detailed analysis or discussion but indicates a superficial interaction.

ImpactNeutral impact

The impact seems negligible given the lack of detailed discourse, suggesting that the conversation does not significantly influence or alter opinions on the article.

Abstract in brief

The study examined whether high doses of morphine used at home for cancer pain relief are feasible and if they impact patient survival, finding that higher doses are associated with specific cancer types and patient characteristics but do not significantly affect overall survival.
Researchers analyzed data from 661 hospice outpatients, noting that most patients received between 52.99 mg and 299 mg of morphine daily, with a smaller group receiving very high doses over 600 mg, and found that older patients and those with gastrointestinal, lung, ovarian, brain tumors, or bone metastases often required higher doses.
The study concluded that administering high-dose morphine at home is manageable and does not increase adverse effects, suggesting a level of safety and feasibility in using high doses for effective pain management in terminal cancer patients.]

Read the full abstract